<?xml version='1.0' encoding='utf-8'?>
<document id="28772281"><sentence text="Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer."><entity charOffset="40-50" id="DDI-PubMed.28772281.s1.e0" text="linsitinib" /><entity charOffset="81-90" id="DDI-PubMed.28772281.s1.e1" text="erlotinib" /><entity charOffset="118-127" id="DDI-PubMed.28772281.s1.e2" text="erlotinib" /><entity charOffset="134-142" id="DDI-PubMed.28772281.s1.e3" text="platinum" /><pair ddi="false" e1="DDI-PubMed.28772281.s1.e0" e2="DDI-PubMed.28772281.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28772281.s1.e0" e2="DDI-PubMed.28772281.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28772281.s1.e0" e2="DDI-PubMed.28772281.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28772281.s1.e0" e2="DDI-PubMed.28772281.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28772281.s1.e1" e2="DDI-PubMed.28772281.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28772281.s1.e1" e2="DDI-PubMed.28772281.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28772281.s1.e1" e2="DDI-PubMed.28772281.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28772281.s1.e2" e2="DDI-PubMed.28772281.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28772281.s1.e2" e2="DDI-PubMed.28772281.s1.e3" /></sentence><sentence text="Maintenance therapy is important in advanced/metastatic non-small cell lung cancer (NSCLC)" /><sentence text=" Erlotinib as switch maintenance following platinum-based chemotherapy increases survival"><entity charOffset="1-10" id="DDI-PubMed.28772281.s3.e0" text="Erlotinib" /><entity charOffset="43-51" id="DDI-PubMed.28772281.s3.e1" text="platinum" /><pair ddi="false" e1="DDI-PubMed.28772281.s3.e0" e2="DDI-PubMed.28772281.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28772281.s3.e0" e2="DDI-PubMed.28772281.s3.e1" /></sentence><sentence text=" Cross-talk between the epidermal growth factor receptor and insulin-like growth factor receptor (IGFR) pathways mediate resistance to individual receptor blockade" /><sentence text=" This study compared maintenance linsitinib plus erlotinib vs erlotinib plus placebo in patients with NSCLC"><entity charOffset="49-58" id="DDI-PubMed.28772281.s5.e0" text="erlotinib" /><entity charOffset="62-71" id="DDI-PubMed.28772281.s5.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.28772281.s5.e0" e2="DDI-PubMed.28772281.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28772281.s5.e0" e2="DDI-PubMed.28772281.s5.e1" /></sentence><sentence text="" /><sentence text="In this Phase II randomised trial, patients without progression following four cycles of first-line platinum-based chemotherapy (N=205) received continuous schedule maintenance oral linsitinib 150 mg or placebo BID combined with erlotinib 150 mg QD for 21-day cycles"><entity charOffset="100-108" id="DDI-PubMed.28772281.s7.e0" text="platinum" /><entity charOffset="229-238" id="DDI-PubMed.28772281.s7.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.28772281.s7.e0" e2="DDI-PubMed.28772281.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28772281.s7.e0" e2="DDI-PubMed.28772281.s7.e1" /></sentence><sentence text=" The primary endpoint was progression-free survival (PFS)" /><sentence text="" /><sentence text="The study was unblinded early due to linsitinib non-superiority" /><sentence text=" No difference was found between the two treatment groups in median PFS of 125 days linsitinib vs 129 days placebo (P=0" /><sentence text="601); no difference in overall survival (OS) was observed" /><sentence text=" Tolerability was similar, although in the linsitinib group, treatment-related adverse events and discontinuations were more frequent"><entity charOffset="43-53" id="DDI-PubMed.28772281.s13.e0" text="linsitinib" /></sentence><sentence text=" No drug-drug interaction was implicated" /><sentence text="" /><sentence text="Linsitinib maintenance therapy added to erlotinib did not improve PFS or OS in non-progressing NSCLC patients"><entity charOffset="0-10" id="DDI-PubMed.28772281.s16.e0" text="Linsitinib" /><entity charOffset="40-49" id="DDI-PubMed.28772281.s16.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.28772281.s16.e0" e2="DDI-PubMed.28772281.s16.e0" /><pair ddi="false" e1="DDI-PubMed.28772281.s16.e0" e2="DDI-PubMed.28772281.s16.e1" /></sentence><sentence text=" This highlights the need for robust biomarkers of response for combinations that incorporate IGFR-targeted therapies in maintenance or other therapeutic settings" /><sentence text="" /></document>